Synthesis and biological activity of a focused library of mitogen-activated protein kinase phosphatase inhibitors

Chemical Biology and Drug Design

Volumn 69, Issue 1, 2007, Pages 23-30

  Arnold, David M ^a   Foster, Caleb ^a,b   Huryn, Donna M ^a   Lazo, John S ^a,b   Johnston, Paul A ^a,b   Wipf, Peter ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Dual specificity phosphatase; Inhibitor synthesis; Library synthesis; Mitogen activated protein kinase phosphatase 1; Molecular Libraries Screening Center Network; PubChem; Quinolines; Uracils

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; STRESS ACTIVATED PROTEIN KINASE;

ARTICLE; BIOLOGICAL ACTIVITY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME SUBSTRATE; PRIORITY JOURNAL;

CELL CYCLE PROTEINS; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; IMMEDIATE-EARLY PROTEINS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PEPTIDE LIBRARY; PHOSPHOPROTEIN PHOSPHATASE; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE-PHOSPHATASE;

EID: 33847138939     PISSN: 17470277     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2007.00474.x     Document Type: Article

References (16)

1. Ducruet A.P., Vogt A., Wipf P., Lazo J.S. (2005) Dual specificity protein phosphatases: therapeutic targets for cancer and Alzheimer's disease. Annu Rev Pharmacol Toxicol;45:725-750.
2. Zhou J.-Y., Liu Y., Wu G.S. (2006) The role of mitogen-activated protein kinase phosphatase-1 in oxidative damage-induced cell death. Cancer Res;66:4888-4894.
3. Johnson T.O., Ermolieff J., Jirousek M.R. (2002) Protein tyrosine phosphatase 1B inhibitors for diabetes. Nat Rev Drug Discov;1:696-709.
4. Lyon M.A., Ducruet A.P., Wipf P., Lazo J.S. (2002) Dual specificity phosphatases as targets for antineoplastic agents. Nat Rev Drug Discov;1:961-976.
5. Barr A.J., Knapp S. (2006) MAPK-specific tyrosine phosphatases: new targets for drug discovery? Trends Pharmacol Sci;27:525-530.
6. Chang L., Karin M. (2001) Mammalian MAP kinase signalling cascades. Nature;410:37-40.
7. Vogt A., Cooley K.A., Brisson M., Tarpley M.G., Wipf P., Lazo J.S. (2003) Cell-active dual specificity phosphatase inhibitors identified by high-content screening. Chem Biol;10:733-742.
8. Vogt A., Tamewitz A., Skoko J., Sikorski R.P., Giuliano K.A., Lazo J.S. (2005) The benzo[c]phenanthridine alkaloid, sanguinarine, is a selective, cell-active inhibitor of mitogen-activated protein kinase phosphatase-1. J Biol Chem;280:19078-19086.
9. Lazo J.S., Nunes R., Skoko J.J., de Oliveira P.E.Q., Vogt A., Wipf P. (2006) Novel benzofuran inhibitors of human mitogen-activated protein kinase phosphatase-1. Bioorg Med Chem;14:5643-5650.
10. Greenberg A.K., Hu J., Basu S., Hay J., Reibman J., Yie T.-A. et al. (2002) Glucocorticoids inhibit lung cancer cell growth through both the extracellular signal-related kinase pathway and cell cycle regulators. Am J Respir Cell Mol Biol;27:320-328.
11. Hutter D., Chen P., Li J., Barnes J., Liu Y. (2002) The carboxyl-terminal domain of MKP-1 and MKP-2 have inhibitory effects on their phosphatase activity. Mol Cell Biochem;233:107-117.
12. Stewart A.E., Dowd S., Keyse S.M., McDonald N.Q. (1999) Crystal structure of the MAPK phosphatase Pyst1 catalytic domain and implications for regulated activation. Nat Struct Biol;6:174-181.
13. Farooq A., Plotnikova O., Chaturvedi G., Yan S., Zeng L., Zhang Q. et al. (2003) Solution structure of the MAPK phosphatase PAC-1 catalytic domain. Insights into substrate-induced enzymatic activation of MKP. Structure;11:155-164.
14. Jeong D.G., Yoon T.-S., Kim J.H., Shim M.Y., Jung S.-K., Son J.H. et al. (2006) Crystal structure of the catalytic domain of human MAP kinase phosphatase 5: structural insight into constitutively active phosphatase. J Mol Biol;360:946-955.
15. Gursoy A., Demirayak S., Capan G., Erol K., Vural K. (2000) Synthesis and preliminary evaluation of new 5-pyrazolinone derivatives as analgesic agents. Eur J Med Chem;35:359-364.
16. Diana G.D., Rudewicz P., Pevear D.C., Nitz T.J., Aldous S.C., Aldous D.J. et al. (1995) Picornavirus inhibitors: trifluoromethyl substitution provides a global protective effect against hepatic metabolism. J Med Chem;38:1355-1371.